Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Lexaria Bioscience (LEXX) over the last 14 years, with Q4 2025 value amounting to $152057.0.

  • Lexaria Bioscience's Receivables - Net fell 5357.11% to $152057.0 in Q4 2025 from the same period last year, while for Nov 2025 it was $152057.0, marking a year-over-year decrease of 5357.11%. This contributed to the annual value of $432371.0 for FY2025, which is 17989.34% up from last year.
  • Lexaria Bioscience's Receivables - Net amounted to $152057.0 in Q4 2025, which was down 5357.11% from $432371.0 recorded in Q3 2025.
  • Lexaria Bioscience's 5-year Receivables - Net high stood at $954097.0 for Q2 2021, and its period low was $136796.0 during Q1 2023.
  • For the 5-year period, Lexaria Bioscience's Receivables - Net averaged around $348937.4, with its median value being $329335.5 (2024).
  • In the last 5 years, Lexaria Bioscience's Receivables - Net surged by 27568.79% in 2021 and then plummeted by 8376.81% in 2022.
  • Lexaria Bioscience's Receivables - Net (Quarter) stood at $461512.0 in 2021, then tumbled by 37.96% to $286322.0 in 2022, then soared by 86.76% to $534731.0 in 2023, then plummeted by 38.75% to $327505.0 in 2024, then crashed by 53.57% to $152057.0 in 2025.
  • Its Receivables - Net was $152057.0 in Q4 2025, compared to $432371.0 in Q3 2025 and $358129.0 in Q2 2025.